Pancreatic cancer remains one of the deadliest cancers in India, with most cases detected too late for cure. A new mRNA vaccine is showing early promise in trials, but experts say its role, cost and real-world impact remain unclear.
Pancreatic cancer is not among India’s most common cancers, but it is among the most lethal. It is often detected late, spreads quickly, and remains difficult to treat even with advances in oncology. That is why a new personalised mRNA vaccine — designed to train the immune system to recognise cancer — is drawing global attention.